Brief: Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
01/04/2025 12:08
April 1 (Reuters) - Alkermes Plc ALKS.O: ALKERMES ANNOUNCES INITIATION OF VIBRANCE-3 PHASE 2 STUDY EVALUATING ALKS 2680 FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA Source text: ID:nPre9pMTva Further company coverage: ALKS.O ((Reuters.Briefs@thomsonreuters.com;))